Taiho Pharmaceutical Co., Ltd.Araris Biotech AGTaiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s technology in two candidates. The Czech biotech disclosed the update on the ...

ADCs are designed to selectively deliver cytotoxic drugs (payloads) to cancer cells by attaching them to antibodies that bind specifically to cancer cells through linkers. Foundational to its ...

Antibody-drug conjugates (ADCs) are new drugs that combine a monoclonal antibody with a chemotherapy drug. They can specifically target cancer cells to deliver potent chemotherapy drugs.

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well with its antibody-drug conjugates (ADCs). Ivonescimab remains the ...

(Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said ...

Myris, formerly known as BioHybrid Solutions, has built on its history in enzyme bioconjugate development to emerge as a new Antibody Drug Conjugate (ADC) therapeutics company focused on the ...